Cleared Traditional

LYRA PARAINFLUENZA VIRUS ASSAY

K141927 · Quidel Corporation · Microbiology
Oct 2014
Decision
85d
Days
Class 2
Risk

About This 510(k) Submission

K141927 is an FDA 510(k) clearance for the LYRA PARAINFLUENZA VIRUS ASSAY, a Parainfluenza Multiplex Nucleic Acid Assay (Class II — Special Controls, product code OOU), submitted by Quidel Corporation (Athens, US). The FDA issued a Cleared decision on October 9, 2014, 85 days after receiving the submission on July 16, 2014. This device falls under the Microbiology review panel. Regulated under 21 CFR 866.3980.

Submission Details

510(k) Number K141927 FDA.gov
FDA Decision Cleared SESE
Date Received July 16, 2014
Decision Date October 09, 2014
Days to Decision 85 days
Submission Type Traditional
Review Panel Microbiology (MI)
Summary Summary PDF

Device Classification

Product Code OOU — Parainfluenza Multiplex Nucleic Acid Assay
Device Class Class II — Special Controls
CFR Regulation 21 CFR 866.3980
Definition A Parainfluenza Multiplex Nucleic Acid Assay Is A Multiplex In Vitro Diagnostic Test For The Simultaneous Qualitative Detection And Discrimination Of Parainfluenza 1 Virus, Parainfluenza 2 Virus, Parainfluenza 3 Virus And Parainfluenza 4 Virus Nucleic Acids Isolated And Purified From Human Respiratory Specimens Obtained From Individuals Exhibiting Signs And Symptoms Of Respiratory Tract Infections Or Viral Culture. The Detection And Discrimination Of Human Parainfluenza Nucleic Acids From Symptomatic Patients Aid In The Diagnosis Of Human Respiratory Tract Parainfluenza Infections If Used In Conjunction With Other Clinical And Laboratory Findings.